Clinical Trial Update: An Open-label Study of GB261 in Refractory Seropositive Systemic Lupus Erythematosus [Phase 1]

View source ↗

Summary

An open-label Phase 1 trial of GB261 for refractory seropositive systemic lupus erythematosus is currently not recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Systemic Lupus Erythematosus

Drugs mentioned

• GB261

Snippet

Sponsor: Union Hospital, Tongji Medical College, Huazhong University of Science and Technology | Conditions: Systemic Lupus Erythematosus (SLE) | Phase 1 | Status: NOT_YET_RECRUITING